Stevenage, United Kingdom

Sjoerd N Wadman

This inventor holds 1 USPTO granted patent. Top assignee: Glaxo Group Limited. Active years: 1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sjoerd N Wadman. Retrieved from https://idiyas.com/inventor/sjoerd-n-wadman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sjoerd N Wadman: Innovator in Benzofuran Derivatives

Introduction

Sjoerd N Wadman is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceuticals, particularly through his work on benzofuran derivatives.

Latest Patents

Wadman holds a patent for "Benzofuran derivatives as 5-HT.sub.1 -like receptor antagonists." This innovation showcases his expertise in developing compounds that may have therapeutic applications in treating various conditions.

Career Highlights

Sjoerd N Wadman is associated with Glaxo Group Limited, a prominent company in the pharmaceutical industry. His work there has allowed him to focus on innovative research and development.

Collaborations

Wadman has collaborated with Peter C North, further enhancing the research efforts within their team. Their combined expertise contributes to the advancement of pharmaceutical innovations.

Conclusion

Sjoerd N Wadman is a distinguished inventor whose work on benzofuran derivatives exemplifies the impact of innovative research in the pharmaceutical sector. His contributions continue to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…